Company intelligence / Profile preview

Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.

Liaoning, China

Ownership: Private
Development stage: Other

Overview

Conducting clinical trials on autologous immune cell therapies including DC-CIK for advanced solid tumors (NCT07260058, Phase I/II with chemotherapy) and stem cell therapy for Parkinson's Disease (NCT07232147). Pre-clinical/animal data shows tumor inhibition without significant toxicity.

Therapeutic areas: OncologyNeurology
Modalities: Cell therapy
Industry: Biotech

Drug pipeline

1 asset

autologous DC-CIK and NK cell therapy

Unknown

Partnerships

Liaoning Cancer Hospital & Institute

Beyond the preview

Go deeper on Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd..

Explore the full profile